LARVA: An integrative framework for large-scale analysis of recurrent variants in noncoding annotations

Nucleic Acids Research

Volumn 43, Issue 17, 2015, Pages 8123-8134

  Lochovsky, Lucas ^a   Zhang, Jing ^a   Fu, Yao ^a   Khurana, Ekta ^b   Gerstein, Mark ^a,c  

^a YALE UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Yale University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BINDING SITE; BREAST CANCER; CALCULATION; CALIBRATION; DEAMINATION; DNA DAMAGE; DNA REPLICATION; HUMAN; KIDNEY CANCER; LUNG ADENOCARCINOMA; LUNG CANCER; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MEIOSIS; MUTATION RATE; NEOPLASM; NEUROBLASTOMA; ONLINE SYSTEM; POINT MUTATION; PRIORITY JOURNAL; VALIDITY; COMPUTER PROGRAM; GENETICS; GENOME; GENOMICS; MOLECULAR GENETICS; MUTATION; PROCEDURES; REGULATORY SEQUENCE;

GENOME; GENOMICS; HUMANS; MOLECULAR SEQUENCE ANNOTATION; MUTATION; MUTATION RATE; NEOPLASMS; REGULATORY SEQUENCES, NUCLEIC ACID; SOFTWARE;

EID: 84949034526     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkv803     Document Type: Article

References (60)

1. Barbieri, C.E., Baca, S.C., Lawrence, M.S., Demichelis, F., Blattner, M., Theurillat, J.P., White, T.A., Stojanov, P., Van Allen, E., Stransky, N. et al. (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet., 44, 685-689.
2. Baca, S.C., Prandi, D., Lawrence, M.S., Mosquera, J.M., Romanel, A., Drier, Y., Park, K., Kitabayashi, N., MacDonald, T.Y., Ghandi, M. et al. (2013) Punctuated evolution of prostate cancer genomes. Cell, 153, 666-677.
3. Grasso, C.S., Wu, Y.M., Robinson, D.R., Cao, X., Dhanasekaran, S.M., Khan, A.P., Quist, M.J., Jing, X., Lonigro, R.J., Brenner, J.C. et al. (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature, 487, 239-243.
4. Shi, L., Zhang, X., Golhar, R., Otieno, F.G., He, M., Hou, C., Kim, C., Keating, B., Lyon, G.J., Wang, K. et al. (2013) Whole-genome sequencing in an autism multiplex family. Mol. autism, 4, 8-22.
5. Almasy, L., Dyer, T.D., Peralta, J.M., Jun, G., Wood, A.R., Fuchsberger, C., Almeida, M.A., Kent, J.W., Fowler, S., Blackwell, T.W. et al. (2014) Data for Genetic Analysis Workshop 18: human whole genome sequence, blood pressure, and simulated phenotypes in extended pedigrees. BMC Proc., 8, S2-S10.
6. Tervasmaki, A., Winqvist, R., Jukkola-Vuorinen, A. and Pylkas, K. (2014) Recurrent CYP2C19 deletion allele is associated with triple-negative breast cancer. BMC Cancer, 14, 902-908.
7. Stefansson, O.A., Moran, S., Gomez, A., Sayols, S., Arribas-Jorba, C., Sandoval, J., Hilmarsdottir, H., Olafsdottir, E., Tryggvadottir, L., Jonasson, J.G. et al. (2014) A DNA methylation-based definition of biologically distinct breast cancer subtypes. Mol. Oncol., 9, 555-568.
8. Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M.C., Zimmerman, L.J., Shaddox, K.F., Kim, S. et al. (2014) Proteogenomic characterization of human colon and rectal cancer. Nature, 513, 382-387.
9. Chen, X., Iliopoulos, D., Zhang, Q., Tang, Q., Greenblatt, M.B., Hatziapostolou, M., Lim, E., Tam, W.L., Ni, M., Chen, Y. et al. (2014) XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature, 508, 103-107.
10. Kurtova, A.V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S.P., Chen, F., Roh, T.T., Lay, E., Ho, P.L. et al. (2014) Blocking PGE-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature, 517, 209-213.
11. Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., Carter, S.L., Stewart, C., Mermel, C.H., Roberts, S.A. et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499, 214-218.
12. Rudd, M.L., Mohamed, H., Price, J.C., AJ, O.H., Le Gallo, M., Urick, M.E., Cruz, P., Zhang, S., Hansen, N.F., Godwin, A.K. et al. (2014) Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1. BMC Cancer, 14, 884-892.
13. Long, G.V., Fung, C., Menzies, A.M., Pupo, G.M., Carlino, M.S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J.F., Saw, R.P. et al. (2014) Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat. Commun., 5, 5694-5702.
14. Yadav, M., Jhunjhunwala, S., Phung, Q.T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T.K., Fritsche, J., Weinschenk, T. et al. (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature, 515, 572-576.
15. Youn, A. and Simon, R. (2011) Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics, 27, 175-181.
16. Consortium, E.P. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature, 489, 57-74.
17. Gerstein, M.B., Rozowsky, J., Yan, K.K., Wang, D., Cheng, C., Brown, J.B., Davis, C.A., Hillier, L., Sisu, C., Li, J.J. et al. (2014) Comparative analysis of the transcriptome across distant species. Nature, 512, 445-448.
18. Fu, Y., Liu, Z., Lou, S., Bedford, J., Mu, X., Yip, K.Y., Khurana, E. and Gerstein, M. (2014) FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer. Genome Biology, 15, 480-494.
19. Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N. and Stratton, M.R. (2004) A census of human cancer genes. Nat. Rev. Cancer, 4, 177-183.
20. Dees, N.D., Zhang, Q., Kandoth, C., Wendl, M.C., Schierding, W., Koboldt, D.C., Mooney, T.B., Callaway, M.B., Dooling, D., Mardis, E.R. et al. (2012) MuSiC: identifying mutational significance in cancer genomes. Genome Res., 22, 1589-1598.
21. Vinagre, J., Almeida, A., Populo, H., Batista, R., Lyra, J., Pinto, V., Coelho, R., Celestino, R., Prazeres, H., Lima, L. et al. (2013) Frequency of TERT promoter mutations in human cancers. Nat. Commun., 4, 2185-2190.
22. Maurano, M.T., Humbert, R., Rynes, E., Thurman, R.E., Haugen, E., Wang, H., Reynolds, A.P., Sandstrom, R., Qu, H., Brody, J. et al. (2012) Systematic localization of common disease-associated variation in regulatory DNA. Science, 337, 1190-1195.
23. Grossman, S.R., Andersen, K.G., Shlyakhter, I., Tabrizi, S., Winnicki, S., Yen, A., Park, D.J., Griesemer, D., Karlsson, E.K., Wong, S.H. et al. (2013) Identifying recent adaptations in large-scale genomic data. Cell, 152, 703-713.
24. Weinhold, N., Jacobsen, A., Schultz, N., Sander, C. and Lee, W. (2014) Genome-wide analysis of noncoding regulatory mutations in cancer. Nat. Genet., 46, 1160-1165.
25. Erturk, E., Cecener, G., Polatkan, V., Gokgoz, S., Egeli, U., Tunca, B., Tezcan, G., Demirdogen, E., Ak, S. and Tasdelen, I. (2014) Evaluation of genetic variations in miRNA-binding sites of BRCA1 and BRCA2 genes as risk factors for the development of early-onset and/or familial breast cancer. Asian Pac. J. Cancer Prev., 15, 8319-8324.
26. Medrzycki, M., Zhang, Y., Zhang, W., Cao, K., Pan, C., Lailler, N., McDonald, J.F., Bouhassira, E.E. and Fan, Y. (2014) Histone h1.3 suppresses h19 noncoding RNA expression and cell growth of ovarian cancer cells. Cancer Res., 74, 6463-6473.
27. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Borresen-Dale, A.L. et al. (2013) Signatures of mutational processes in human cancer. Nature, 500, 415-421.
28. Cancer Genome Atlas Research Network. (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455, 1061-1068.
29. Berger, M.F., Lawrence, M.S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A.Y., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C. et al. (2011) The genomic complexity of primary human prostate cancer. Nature, 470, 214-220.
30. Weischenfeldt, J., Simon, R., Feuerbach, L., Schlangen, K., Weichenhan, D., Minner, S., Wuttig, D., Warnatz, H.J., Stehr, H., Rausch, T. et al. (2013) Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell, 23, 159-170.
31. Wang, K., Yuen, S.T., Xu, J., Lee, S.P., Yan, H.H., Shi, S.T., Siu, H.C., Deng, S., Chu, K.M., Law, S. et al. (2014) Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet., 46, 573-582.
32. Cancer Genome Atlas Research Network, Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C. and Stuart, J.M. (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet., 45, 1113-1120.
33. Hodgkinson, A. and Eyre-Walker, A. (2011) Variation in the mutation rate across mammalian genomes. Nat. Rev. Genet., 12, 756-766.
34. Derrien, T., Estelle, J., Marco Sola, S., Knowles, D.G., Raineri, E., Guigo, R. and Ribeca, P. (2012) Fast computation and applications of genome mappability. PLoS One, 7, e30377.
35. Quinlan, A.R. and Hall, I.M. (2010) BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics, 26, 841-842.
36. Harrow, J., Frankish, A., Gonzalez, J.M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B.L., Barrell, D., Zadissa, A., Searle, S. et al. (2012) GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res., 22, 1760-1774.
37. Rozowsky, J., Euskirchen, G., Auerbach, R.K., Zhang, Z.D., Gibson, T., Bjornson, R., Carriero, N., Snyder, M. and Gerstein, M.B. (2009) PeakSeq enables systematic scoring of ChIP-seq experiments relative to controls. Nat. Biotechnol., 27, 66-75.
38. Yip, K.Y., Cheng, C., Bhardwaj, N., Brown, J.B., Leng, J., Kundaje, A., Rozowsky, J., Birney, E., Bickel, P., Snyder, M. et al. (2012) Classification of human genomic regions based on experimentally determined binding sites of more than 100 transcription-related factors. Genome Biol., 13, R48-R69.
39. Thurman, R.E., Rynes, E., Humbert, R., Vierstra, J., Maurano, M.T., Haugen, E., Sheffield, N.C., Stergachis, A.B., Wang, H., Vernot, B. et al. (2012) The accessible chromatin landscape of the human genome. Nature, 489, 75-82.
40. Bejerano, G., Pheasant, M., Makunin, I., Stephen, S., Kent, W.J., Mattick, J.S. and Haussler, D. (2004) Ultraconserved elements in the human genome. Science, 304, 1321-1325.
41. Khurana, E., Fu, Y., Colonna, V., Mu, X.J., Kang, H.M., Lappalainen, T., Sboner, A., Lochovsky, L., Chen, J., Harmanci, A. et al. (2013) Integrative annotation of variants from 1092 humans: application to cancer genomics. Science, 342, 1235587-1235597.
42. Ding, L., Wendl, M.C., Koboldt, D.C. and Mardis, E.R. (2010) Analysis of next-generation genomic data in cancer: accomplishments and challenges. Hum. Mol. Genet., 19, R188-R196.
43. Young-Xu, Y. and Chan, K.A. (2008) Pooling overdispersed binomial data to estimate event rate. BMC Med. Res. Methodol., 8, 58-69.
44. Kleinman, J.C. (1975) Proportions with extraneous variance: two dependent samples. Biometrics, 31, 737-743.
45. Stamatoyannopoulos, J.A., Adzhubei, I., Thurman, R.E., Kryukov, G.V., Mirkin, S.M. and Sunyaev, S.R. (2009) Human mutation rate associated with DNA replication timing. Nat. Genet., 41, 393-395.
46. Tian, D., Wang, Q., Zhang, P., Araki, H., Yang, S., Kreitman, M., Nagylaki, T., Hudson, R., Bergelson, J. and Chen, J.Q. (2008) Single-nucleotide mutation rate increases close to insertions/deletions in eukaryotes. Nature, 455, 105-108.
47. Hollister, J.D., Ross-Ibarra, J. and Gaut, B.S. (2010) Indel-associated mutation rate varies with mating system in flowering plants. Mol. Biol. Evol., 27, 409-416.
48. McDonald, M.J., Wang, W.C., Huang, H.D. and Leu, J.Y. (2011) Clusters of nucleotide substitutions and insertion/deletion mutations are associated with repeat sequences. PLoS Biol., 9, e1000622.
49. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B., 57, 289-300.
50. Kwon, Y.J., Lee, S.J., Koh, J.S., Kim, S.H., Lee, H.W., Kang, M.C., Bae, J.B., Kim, Y.J. and Park, J.H. (2012) Genome-wide analysis of DNA methylation and the gene expression change in lung cancer. J. Thorac. Oncol., 7, 20-33.
51. Isogai, E., Ohira, M., Ozaki, T., Oba, S., Nakamura, Y. and Nakagawara, A. (2011) Oncogenic LMO3 collaborates with HEN2 to enhance neuroblastoma cell growth through transactivation of Mash1. PLoS One, 6, e19297.
52. Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S., Eppig, J.T. et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet., 25, 25-29.
53. Filippova, G.N. (2008) Genetics and epigenetics of the multifunctional protein CTCF. Curr. Top. Dev. Biol., 80, 337-360.
54. Ohlsson, R., Renkawitz, R. and Lobanenkov, V. (2001) CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet., 17, 520-527.
55. Takai, D., Gonzales, F.A., Tsai, Y.C., Thayer, M.J. and Jones, P.A. (2001) Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum. Mol. Genet., 10, 2619-2626.
56. Maldonado, V. and Melendez-Zajgla, J. (2011) Role of Bcl-3 in solid tumors. Mol. Cancer, 10, 152-158.
57. Shendure, J. and Ji, H. (2008) Next-generation DNA sequencing. Nat. Biotechnol., 26, 1135-1145.
58. Koch, L. (2014) Cancer genomics: non-coding mutations in the driver seat. Nat. Rev. Genet., 15, 574-575.
59. Lin, P.C., Chiu, Y.L., Banerjee, S., Park, K., Mosquera, J.M., Giannopoulou, E., Alves, P., Tewari, A.K., Gerstein, M.B., Beltran, H. et al. (2013) Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res., 73, 1232-1244.
60. Kim, Y.M., Sharma, N. and Nyborg, J.K. (2008) The proto-oncogene Bcl3, induced by Tax, represses Tax-mediated transcription via p300 displacement from the human T-cell leukemia virus type 1 promoter. J. Virol., 82, 11939-11947.